Enabling Investments (SDD)
Abstract
The Enabling Investments System Development & Demonstration (SDD) Project provides the capability to rapidly develop, manufacture, and approve medical countermeasures through sustaining the Department of Defense advanced development manufacturing facility. Enabling efforts in this area support dedicated infrastructure capabilities, demonstrations, and overarching development support functions as portfolio enablers responding to emerging threats. Additional efforts facilitate incorporation of chemical and biological (CB) survivability equipment into service major acquisition programs. Efforts included in this Project are: (1) Chemical Biological Incident Preparedness and Response - Advanced Development and Manufacturing (CBIPR-ADM) (2) Chemical Biological Incident Preparedness and Response - Secure Biolaboratory Consortium (CBIPR-SBC) (3) Major Defense Acquisition Program (MDAP) The CBIPR-ADM ensures prioritization to domestic biopharmaceutical manufacturing capacities, capabilities, and infrastructure (e.g. the DoD-ADM Facility and other strategic partners) that are operationally ready to rapidly develop and manufacture medical countermeasures (MCMs) against current and emerging chemical and biological threats including pandemic response. Prioritization is achieved by establishing and enhancing proven biopharmaceutical manufacturing platform technologies and infrastructure at these facilities. Thus, these facilities will have the capability to accelerate development of MCMs at all stages of development, enhance preparedness for existing threats, and rapidly respond to emerging threats as part of a medical integrated layered defense. MCMs that benefit from these efforts include: Vaccines for Viral Agents, Vaccines for Bacterial Agents and Toxins, monoclonal antibodies, antibody fragments and conjugates for therapeutic and prophylactic use across all agent classes. In FY25, CBIPR-ADM transitions to CBIPR-SBC based on current incident preparedness and response requirements. The Chemical Biological Incident Preparedness and Response – Secure Biolaboratory Consortium (CBIPR-SBC ) program will establish a robust capability to analyze and characterize inbound threat samples and nucleic acid sequences in classified environment for risk stratification, understanding of pathogenic potential, and response strategy development. Inherent to both characterization and drug development are requirements for a robust laboratory infrastructure up to biosafety level 4 (BSL-4) that can work with highly classified (up to TS/SCI) intelligence data. This capability can be utilized across the Chemical Biological Defense (CBD) Enterprise and will support the GUIDE program to include “live fire” exercises. The MDAP CBRN Survivability Support and Services (CS3) initiative provides enabling support to DoD programs designated as CBRN Mission Critical or requiring CBRN capabilities. Enabling support facilitates alignment with CBRN capabilities through the following: acquisition strategy, systems engineering, CBRN assessment, technical requirements analysis and management, customized CBRN defense solutions for each weapon system program, development, and integration of CBRN equipment, test and evaluation support, logistics support, modeling and simulation support, documentation, technical review support, IPT support, and/or CBRN subject matter expertise.
Document Details
- Document Type
- Project
- Publication Date
- Oct 01, 2025
- Source ID
- EN5_0604384BP_5_0400_PB_2025
Related Documents
- Root: Chemical and Biological Defense Program - EMD
- Child Accomplishment: 1) CBIPR-ADM
- Child Accomplishment: 2) CBIPR-SBC
- Child Accomplishment: 3) MDAP
- Child Cost Item: 517d779aa74019e976d6f52345118fb0
- Child Cost Item: c0d11d4a04885297fce32b6796130de2
- Child Cost Item: eb6185a0f901581fa1136df9dc8bf10f
- Child Cost Item: 199d849166d05349da4db9e482e5891b
- Child Cost Item: 1f21a8be96e9926c0b945bdc0b5a08a6
- Child Cost Item: 203b9e5ac41053ad044565778afa5b11
- Child Cost Item: f81eb0df72125bf0efedc7d22b9da18c